Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 14/20 | 0.73 |
| ▸ | MTOR | P42345 | 9/20 | 0.73 |
| ▸ | ATR | Q13535 | 8/20 | 0.50 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.49 |
| ▸ | PRKDC | P78527 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8003220 | 0.89 | PIK3CA (0.78) | PIK3CAMTORATRPIK3R1PIK3CD | |
| SCHEMBL8003295 | 0.85 | PIK3CA (0.82) | PIK3CAMTORATRPIK3R1PIK3CD | |
| SCHEMBL8012909 | 0.85 | PIK3CA (0.73) | PIK3CAMTORATRPIK3R1PIK3CD | |
| SCHEMBL1309409 | 0.85 | PIK3CA (0.70) | PIK3CAMTORATRPIK3R1PIK3CD | |
| SCHEMBL8008189 | 0.84 | PIK3CA (1.00) | PIK3CAMTORATRPIK3R1PIK3CD | |
| SCHEMBL8010317 | 0.84 | PIK3CA (0.74) | PIK3CAMTORATRPIK3R1PIK3CD | |
| SCHEMBL8012481 | 0.84 | PIK3CA (0.79) | PIK3CAMTORATRPIK3R1PIK3CD | |
| SCHEMBL8008317 | 0.83 | PIK3CA (0.70) | PIK3CAMTORATRPIK3R1PIK3CD | |
| SCHEMBL8012360 | 0.83 | PIK3CA (0.86) | PIK3CAMTORATRPIK3R1PIK3CD | |
| SCHEMBL8003292 | 0.83 | PIK3CA (0.80) | PIK3CAMTORATRPIK3R1PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009093981-A1 | TRIAZINE COMPOUNDS AS KINASE INHIBITORS | S BIO PTE LTD (SG) | 2009-07-30 | — | — | WO | disclosed |